Brief review: Nondepolarizing neuromuscular blocking drugs and critical illness myopathy

Canadian Journal of Anesthesia

Volumn 53, Issue 11, 2006, Pages 1148-1156

  Murray, Michael J ^a   Brull, Sorin J ^a   Bolton, Charles F ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR; CORTICOSTEROID; CYTOKINE; HYDROCORTISONE; NEUROMUSCULAR BLOCKING AGENT; NICOTINIC RECEPTOR; SODIUM CHANNEL; VECURONIUM;

ARTIFICIAL VENTILATION; ASTHMATIC STATE; CLINICAL PROTOCOL; CRITICAL ILLNESS; CRITICAL ILLNESS MYOPATHY; CRITICALLY ILL PATIENT; DRUG OVERDOSE; HIGH RISK PATIENT; HUMAN; MUSCLE WEAKNESS; MYOPATHY; NEUROMUSCULAR BLOCKING; NUTRITIONAL SUPPORT; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANESTHESIA; CRITICAL ILLNESS; HUMANS; MUSCULAR DISEASES; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 33751054939     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022883     Document Type: Review

References (52)

1. Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31: 1012-6.
2. Anzueto A. Muscle dysfunction in the intensive care unit. Clin Chest Med 1999; 20: 435-52.
3. Leijten FS, de Letter MA, Op de Coul AA. 'Critical-illness'-polyneuropathie-myopathie (Dutch). Ned Tijdschr Geneeskd 2000; 144: 1428-32.
4. Kane SL, Dasta JF. Clinical outcomes of critical illness polyneuropathy. Pharmacotherapy 2002; 22: 373-9.
5. Rudis MI, Guslits BJ, Peterson EL, et al. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 1996; 24: 1749-56.
6. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327: 524-8.
7. Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 2001; 248: 929-34.
8. Hund E. Myopathy in critically ill patients. Crit Care Med 1999; 27: 2544-7.
9. Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992; 42: 2082-7.
10. Deconinck N, Van Parijs V, Beckers-Bleukx G, Van den Bergh P. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Discord 1998; 8: 186-92.
11. Hoke A, Rewcastle NB, Zochodne DW. Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies. Can J Neurol Sci 1999; 26: 325-9.
12. Henderson RD, Lawn ND, Fletcher DD, McClelland RL, Wijdicks EF. The morbidity of Guillain-Barre syndrome admitted to the intensive care unit. Neurology 2003; 60: 17-21.
13. Polsonetti BW, Joy SD, Laos LF. Steroid-induced myopathy in the ICU. Ann Pharmacother 2002; 36: 1741-4.
14. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005; 32: 140-63.
15. Op de Coul AA, Lambregts PC, Koeman J, van Puyenbroek MJ, Ter Laak HJ, Gabreels-Festen AA. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosurg 1985; 87: 17-22.
16. Mascia MF, Koch M, Medicis JJ. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care. Crit Care Med 2000; 28: 2300-6.
17. Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996; 46: 731-6.
18. Danon MJ, Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium. during steroid treatment. Muscle Nerve 1991; 14: 1131-9.
19. de Letter MA, Schmitz PI, Visser LH, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001; 29: 2281-6.
20. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit. A prospective multicenter study. JAMA 2002; 288: 2859-67.
21. Lacomis D. Critical illness myopathy. Curr Rheumatol Rep 2002; 4: 403-8.
22. De Jonghe B, Sharshar T, Hopkinson N, Outin H. Paresis following mechanical ventilation. Curr Opin Crit Care 2004; 10: 47-52.
23. Kupfer Y, Namba T, Kaldawi E, Tessler S. Prolonged weakness after long-term infusion of vecuronium bromide. Ann Intern Med 1992; 117: 484-6.
24. Davis NA, Rodgers JE, Gonzalez ER, Fowler AA III. Prolonged weakness after cisatracurium infusion: a case report. Crit Care Med 1998; 26: 1290-2.
25. Rubio ER, Seelig CB. Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids. South Med J 1996; 89: 624-6.
26. Coursin DB, Prielipp RC. Prolonged paralysis with atracurium infusion (Letter). Crit Care Med 1995; 23: 1155-6.
27. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994; 22: 884-93.
28. Zochodne DW, Bolton CF, Wells, GA, et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain 1987; 110(Pt 4): 819-41.
29. Leijten FS, Harinck de Weerd JE, Poortvliet DC, de Weerd AW. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995; 274: 1221-5.
30. Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997; 20: 665-73.
31. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996; 347: 1579-82.
32. Hansen-Flaschen J, Cowen J, Raps EC. Neuromuscular blockade in the intensive care unit. More than we bargained for. Am Rev Respir Dis 1993; 147: 234-6.
33. Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25: 575-83.
34. Dodson BA, Kelly BJ, Braswell LM, Cohen NH. Changes in acetylcholine receptor number in muscle from critically ill patients receiving muscle relaxants: an investigation of the molecular mechanism of prolonged paralysis. Crit Care Med 1995; 23: 815-21.
35. Mauch DH, Nagler K, Schumacher S, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001; 294: 1354-7.
36. Bretscher MS, Munro S. Cholesterol and the Golgi apparatus. Science 1993; 261: 1280-1.
37. Rehberg B, Urban BW, Duch DS. The membrane lipid cholesterol modulates anesthetic actions on a human brain ion channel. Anesthesiology 1995; 82: 749-58.
38. Mizuguchi KA, Takakuwa Y, Itoh E, Suzuki H. Membrane fusion of erythrocytes as a model study of the effects of muscle relaxants on presynaptic exocytosis. Anesth Analg 1994; 78: 1077-81.
39. Rich MM, Pinter MJ. Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 2001; 50: 26-33.
40. Goh AY, Chan PW. Acute myopathy after status asthmaticus: steroids, myorelaxants or carbon dioxide? Respirology 1999; 4: 97-9.
41. Road J, Mackie G, Jiang TX, Stewart H, Eisen A. Reversible paralysis with status asthmaticus, steroids, and pancuronium: clinical electrophysiological correlates. Muscle Nerve 1997; 20: 1587-90.
42. Griffin D, Fairman N, Coursin D, Rawsthorne L, Grossman JE. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992; 102: 510-4.
43. Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000; 28: 34-45.
44. Behbehani NA, Al-Mane F, D'yachkova Y, Pare P, FitzGerald JM. Myopathy following mechanical ventilation for acute severe asthma. The role of muscle relaxants and corticosteroids. Chest 1999; 115: 1627-31.
45. Ibebunjo C, Martyn JA. Fiber atrophy, but not changes in acetylcholine receptor expression, contributes to the muscle dysfunction after immobilization. Crit Care Med 1999; 27: 275-85.
46. Kindler CH, Verotta D, Gray AT, Gropper MA, Yost S. Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium. Anesthesiology 2000; 92: 821-32.
47. Gronert GA. Disuse atrophy with resistance to pancuronium. Anesthesiology 1981; 55: 547-9.
48. Khuenl-Brady KS, Reitstatter B, Schlager A, et al. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994; 78: 1082-6.
49. Phipps P, Garrard CS. The pulmonary physician in critical care. 12: acute severe asthma in the intensive care unit. Thorax 2003; 58: 81-8.
50. Bellomo R, McLaughlin P, Tai E, Parkin G. Asthma requiring mechanical ventilation. A low morbidity approach. Chest 1994; 105: 891-6.
51. de Lemos JM, Carr RR, Shalansky KF, Bevan DR, Ronco JJ. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion. Crit Care Med 1999; 27: 2648-55.
52. Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002; 30: 142-56.